SBIR Phase I: A Novel Respiratory Ventilator for Clinical Care (COVID-19)

SBIR 第一阶段：用于临床护理的新型呼吸机 (COVID-19)

• 批准号: 2036836
• 负责人: Karl Wassmann
• 金额: $ 25.54万
• 依托单位: SPERRY MEDTECH INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2036836&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Respiratory; Ventilator

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a transformational ventilator design targeted at the unmet clinical need for low-cost ($3000), highly functional, rugged, modular and low maintenance ventilators supporting advanced ventilation modes. Current midrange ventilators cost between $8,000-20,000 with high-end ventilation units costing up to $50,000. The proposed design uses highly efficient and low-cost modern technologies with few moving functional elements. Only four modules are employed, designed to connect together in a quick-release, tool-less fashion requiring no service technicians to maintain. The design ensures that the new ventilator will work in existing hospital and acute care settings by (a) supporting networking of mobile devices for remote monitoring, (b) networking to hospital information systems to integrate with patient records and analytic systems, (c) supporting standard breathing patient circuit tubing and intubation tubes, (d) inclusion of monitoring settings and alarms, (e) supporting the use of hospital oxygen, oxygen in cylinders, medical air and atmospheric air. The global mechanical ventilator market was valued at $2.94 billion in 2019 and is estimated to reach $12.54 billion by 2027, driven by the rising worldwide prevalence of respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD) and asthma, as well as the COVID-19 pandemic. This new design will favorably impact clinical settings including acute care facilities, in-transit systems, home health care and developing countries. It is ideal for surge and scale requirements, such as stockpiling by hospitals, strategic national stockpiles, mass casualty response and humanitarian missions.This SBIR Phase I project leverages applied engineering principles and understanding the mechanics of compressible fluids. It leverages the use of computer-aided design and engineering, 3D printing, networking and low-cost components in consideration of hospital protocols. Novel innovations include: (a) positive displacement, volumetric air motive system for air/O2 delivery, and (b) a multi-position single element rotary selector valve for flow control of the air motive system. An inexpensive bill of materials is achieved with minimal components for low weight (4 pounds not including battery backup), small logistics footprint, minimal component failure points, ease of maintenance and rapid scale of manufacture.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小型企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是开发一种变革性呼吸机设计，旨在满足尚未满足的临床需求，即低成本（3000 美元）、功能强大、坚固耐用、模块化和低维护的呼吸机，支持先进的通气模式。目前中档呼吸机的成本在 8,000 至 20,000 美元之间，高端呼吸机的成本高达 50,000 美元。拟议的设计采用高效、低成本的现代技术，几乎没有移动的功能元件。仅采用四个模块，旨在以快速释放、免工具的方式连接在一起，无需维修技术人员进行维护。该设计确保新型呼吸机能够在现有医院和急症护理环境中工作，方法是：(a) 支持移动设备联网以进行远程监控，(b) 与医院信息系统联网以与患者记录和分析系统集成，(c) 支持标准呼吸患者回路管道和插管，(d) 包含监控设置和警报，(e) 支持使用医院氧气、气瓶氧气、医用空气 和大气。 2019 年，全球机械呼吸机市场价值为 29.4 亿美元，预计到 2027 年将达到 125.4 亿美元，原因是慢性阻塞性肺病 (COPD) 和哮喘等呼吸系统疾病全球患病率不断上升，以及 COVID-19 大流行。这种新设计将对临床环境产生有利影响，包括急症护理设施、转运系统、家庭医疗保健和发展中国家。 它非常适合激增和规模要求，例如医院储备、国家战略储备、大规模伤亡响应和人道主义任务。该 SBIR 第一阶段项目利用了应用工程原理并了解可压缩流体的力学。 它利用计算机辅助设计和工程、3D 打印、网络和低成本组件，并考虑到医院协议。新颖的创新包括：(a) 用于空气/氧气输送的容积式空气动力系统，以及 (b) 用于空气动力系统流量控制的多位单元件旋转选择阀。使用最少的组件实现了廉价的材料清单，重量轻（4 磅，不包括备用电池）、物流足迹小、组件故障点最少、易于维护和快速规模化制造。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优点和更广泛的影响审查标准进行评估，被认为值得支持。